Abstract:In order to improve the effects of medical therapy for cancer, we prepared magnetic nanocomposites (Fe3O4@SiO2–NH–NH[Formula: see text] as doxorubicin (DOX) carriers via two different schemes. Scheme (I): the carriers were synthesized from magnetic silica nanoparticles (Fe3O4@SiO[Formula: see text] via layer by layer modification, scheme (II): the carriers were obtained from amino-modified magnetic silica nanoparticles (Fe3O4@SiO2–NH[Formula: see text] synthesized by one-step, and followed by surface modification. In order to load DOX effectively, the surface of the carriers were further modified to make the surface with a large number of hydrazine bonds which can form a pH-sensitive bond (hydrazone bond) with DOX. The two kinds of carriers both exhibited a size around 80[Formula: see text]nm, high stability and superparamagnetic behavior. However, DOX-loaded carriers (Fe3O4@SiO2–DOX(2)) performed relatively poorer performance in terms of drug loading and releasing (the loading efficiency of DOX decreased from 67.33% to 42.15%, while the releasing efficiency of DOX decreased from 66.16% to 62.23% within 72[Formula: see text]h at pH 4.0). Water-soluble tetrazolium salts (WST-1) assays in cancer cells (Hela) demonstrated that the Fe3O4@SiO2–DOX presented high anti-tumor activity, while the carriers were nearly nontoxic. Thus, the results suggested that the magnetic nanocomposites synthesized by the two different methods both can be employed to deliver DOX, while the carriers obtained via the first method may perform better and would be applied in the field of cancer therapy in the future.

Facile Synthesis of Core-shell Magnetic Mesoporous Silica Nanoparticles for Ph-Sensitive Anticancer Drug Delivery.

Acid-responsive intracellular doxorubicin release from click chemistry functionalized mesoporous silica nanoparticles

Ph-Responsive Magnetic Core-Shell Nanocomposites for Drug Delivery.

Synthesis and Characterization of Mesoporous Magnetic Nanocomposites Wrapped with Chitosan Gatekeepers for Ph-Sensitive Controlled Release of Doxorubicin

Synthesis and Characterization of Doxorubicin Loaded Ph-Sensitive Magnetic Core-Shell Nanocomposites for Targeted Drug Delivery Applications

Fe3O4@mSiO2 Core-Shell Nanocomposite Capped with Disulfide Gatekeepers for Enzyme-Sensitive Controlled Release of Anti-Cancer Drugs.

Facile Synthesis of Ph Sensitive Polymer-Coated Mesoporous Silica Nanoparticles and Their Application in Drug Delivery

Magnetic and Ph-Sensitive Nanoparticles for Antitumor Drug Delivery

Ferrocene-functionalized magnetic core-shell nanoparticles based on hydrosilylation reaction for pH-responsive doxorubicin delivery system

Metal-Phenolic Encapsulated Mesoporous Silica Nanoparticles for Ph-Responsive Drug Delivery and Magnetic Resonance Imaging

A Ph-Responsive Mesoporous Silica Nanoparticle-Based Drug Delivery System for Targeted Breast Cancer Therapy

Facile Synthesis and Magnetic Property of Iron Oxide/Mcm-41 Mesoporous Silica Nanospheres for Targeted Drug Delivery

Amino-functionalized mesoporous silica nanoparticles as efficient carriers for anticancer drug delivery.

Multifunctional Hybrid Silica Nanoparticles for Controlled Doxorubicin Loading and Release with Thermal and Ph Dual Response

Magnetic Nanoparticles with a Ph-Sheddable Layer for Antitumor Drug Delivery

Fibrous-structured magnetic and mesoporous Fe3O 4/silica microspheres: Synthesis and intracellular doxorubicin delivery

Facile Synthesis by a Covalent Binding Reaction for Ph-Responsive Drug Release of Carboxylated Chitosan Coated Hollow Mesoporous Silica Nanoparticles

One-pot Construction of Doxorubicin Conjugated Magnetic Silica Nanoparticles

Investigation of Hollow Mesoporous NiFe2O4 Nanospheres Fabricated Via a Template-Free Solvothermal Route As Ph-Responsive Drug Delivery System for Potential Anticancer Application

Engineering Polyzwitterion And Polydopamine Decorated Doxorubicin-Loaded Mesoporous Silica Nanoparticles As A Ph-Sensitive Drug Delivery

Fabrication of a pH/Redox-Triggered Mesoporous Silica-Based Nanoparticle with Microfluidics for Anticancer Drugs Doxorubicin and Paclitaxel Codelivery